New York, New York
14 March 2013
The DNA of Disruptive Innovation
For the past 30 years pharma has thrived on big molecule breakthroughs and savvy marketing. Spending on healthcare has skyrocketed and is projected to reach 20 percent of GDP by 2020, but that hardly means that the industry will remain unchanged when that day arrives. Pharma has been hurting in fundamental ways. Faced with rising development costs, competition from generics, declining productivity, and the prospect of fewer big volume drugs in the pipeline has squeezed margins and forced layoffs. These forces and others are driving change within the industry.
Chief Executive Magazine and A.T. Kearney met for a private roundtable at A.T. Kearney's New York office. Top leaders from the pharmaceutical and healthcare industries discussed how the pharmaceutical industry can combat disruptive technology and shifting markets in the next decade.
For those of you that missed this great roundtable we will add the proceeding to our site as soon as we receive them, so stay tuned!
- Mike Wise, Partner, A.T. Kearney
- Chris Paddison, Partner, A.T. Kearney
- Rajeev Kapoor, Partner, A.T. Kearney
Europe, Middle East, and Africa